PBandB

PBandB is a private, clinical-stage biotech company pioneering a novel approach in medical aesthetics by developing injectable products designed to remodel fat tissue. Its core technology utilizes plant-derived lipids to stimulate the patient's own fat cells to increase volume, positioning it as a potential superior and more natural alternative to traditional dermal fillers. The company has a strong intellectual property position with 12 patents granted and is targeting two major aesthetic indications: mid-facial volume loss and buttock enhancement. Backed by grant funding and venture capital, and led by a team with bioengineering and clinical development expertise, PBandB is advancing its pipeline toward clinical validation and eventual commercialization in the multi-billion dollar global aesthetics market.

A proprietary injectable technology using plant-derived lipids to stimulate a patient's own adipocytes (fat cells) to increase in volume, enabling natural tissue remodeling for facial and body aesthetics.

PBandB competes in the medical aesthetics market against giants like AbbVie (Allergan), Galderma, and Merz, who dominate with hyaluronic acid and other filler products. Its technology differentiates by stimulating natural fat growth rather than filling space, but it must overcome entrenched products, practitioner habits, and the marketing budgets of incumbents.